Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
HIV Med ; 21(9): 547-556, 2020 10.
Article in English | MEDLINE | ID: mdl-32687684

ABSTRACT

OBJECTIVES: Integration of HIV care with general healthcare may improve patient engagement. We assessed patient outcomes in four clinics offering HIV care integrated into primary care clinics in Yangon, Myanmar. METHODS: We carried out a retrospective cohort analysis of 4551 patients who started antiretroviral therapy between 2009 and 2017. Mortality and disengagement from care were assessed using Cox regression. RESULTS: People living with HIV presented late with low CD4 counts [median (25th , 75th percentile) = 178 (65, 308) from 4216 patients] and advanced HIV (69% with stage 3 or 4). Survival was 0.95 at 1 year and 0.90 at 5 years. Males were at a higher risk of mortality than females [unadjusted hazard ratio (uHR) = 1.6 (95% CI: 1.3-2.0). Patients linked to HIV care via antenatal care or partner/parent notification were at reduced risk of mortality [uHR = 0.4 (95% CI: 0.1-1.0) and uHR = 0.5 (95% CI: 0.3-0.7)] relative to patients who presented for HIV testing. The cumulative incidence of disengagement was 0.06 at 1 year and 0.15 at 5 years. Young adults had a higher risk of disengagement than did children and older patients. Women linked to HIV care via antenatal care services were at increased risk of disengagement relative to patients who came for HIV testing (uHR = 2.4; 95% CI: 1.7-3.4). Mortality and disengagement remained steady over calendar time as the programme scaled up. CONCLUSIONS: HIV care within a primary care model is effective to attain early linkage to care, with high survival. However, close attention should be given to disengagement from care, in particular for pregnant women.


Subject(s)
Anti-Retroviral Agents/therapeutic use , Delivery of Health Care, Integrated/methods , HIV Infections/drug therapy , Medication Adherence/statistics & numerical data , Adult , Female , HIV Infections/mortality , Humans , Male , Myanmar/epidemiology , Prenatal Care , Primary Health Care , Retrospective Studies , Risk Factors , Survival Analysis
4.
Sci Rep ; 7(1): 12132, 2017 09 21.
Article in English | MEDLINE | ID: mdl-28935919

ABSTRACT

It has been suggested recently, based on pharmacokinetic-pharmacodynamic modelling exercises, that twice daily dosing of artemisinins increases malaria parasite killing and so could "dramatically enhance and restore drug effectiveness" in artemisinin resistant P. falciparum malaria infections. It was recommended that split dosing should be incorporated into all artemisinin combination regimen designs. To explain why parasite clearance rates were not faster with split dose regimens it was concluded that splenic malaria parasite clearance capacity was readily exceeded, resulting in the accumulation of dead parasites in the circulation, that parasite clearance was therefore an unreliable measure of drug efficacy, and instead that human immunity is the primary determinant of clearance rates. To test these various hypotheses we performed a logistic meta-regression analysis of cure rates from all falciparum malaria treatment trials (n = 40) with monotherapy arms containing artemisinin or a derivative (76 arms). There was no evidence that split dosing enhanced cure rates.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/drug therapy , Antimalarials/administration & dosage , Antimalarials/pharmacokinetics , Antimalarials/pharmacology , Artemisinins/administration & dosage , Artemisinins/pharmacokinetics , Artemisinins/pharmacology , Dose-Response Relationship, Drug , Humans , Models, Biological , Plasmodium falciparum/drug effects , Regression Analysis , Treatment Outcome
5.
CPT Pharmacometrics Syst Pharmacol ; 3: e132, 2014 Aug 27.
Article in English | MEDLINE | ID: mdl-25163024

ABSTRACT

Dihydroartemisinin-piperaquine is an effective drug in the treatment of Plasmodium falciparum and P. vivax malaria. The objective of this study was to evaluate the population pharmacokinetics and pharmacodynamics of piperaquine in patients with P. vivax malaria in Thailand after a standard regimen of dihydroartemisinin-piperaquine to determine whether residual piperaquine prevents or delays the emergence of P. vivax relapse. Sparse blood samples were collected from 116 patients. Piperaquine pharmacokinetics were described well by a three-compartment distribution model. Relapsing P. vivax malaria was accommodated by a constant baseline hazard (8.94 relapses/year) with the addition of a surge function in a fixed 3-week interval and a protective piperaquine effect. The results suggest that a large proportion of the first relapses were suppressed completely by residual piperaquine concentrations and that recurrences resulted mainly from emergence of the second or third relapse or from reinfection. This suggests a significant reduction in P. vivax morbidity when using dihydroartemisinin-piperaquine compared with other antimalarial drugs with shorter terminal postprophylactic effects.

6.
Nature ; 508(7497): 469-76, 2014 Apr 24.
Article in English | MEDLINE | ID: mdl-24759409

ABSTRACT

The discovery of rare genetic variants is accelerating, and clear guidelines for distinguishing disease-causing sequence variants from the many potentially functional variants present in any human genome are urgently needed. Without rigorous standards we risk an acceleration of false-positive reports of causality, which would impede the translation of genomic research findings into the clinical diagnostic setting and hinder biological understanding of disease. Here we discuss the key challenges of assessing sequence variants in human disease, integrating both gene-level and variant-level support for causality. We propose guidelines for summarizing confidence in variant pathogenicity and highlight several areas that require further resource development.


Subject(s)
Disease , Genetic Predisposition to Disease/genetics , Genetic Variation/genetics , Guidelines as Topic , False Positive Reactions , Genes/genetics , Humans , Information Dissemination , Publishing , Reproducibility of Results , Research Design , Translational Research, Biomedical/standards
7.
Clin Pharmacol Ther ; 91(6): 1001-9, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22549284

ABSTRACT

Eleven years since the initial drafts of the human genome were published, we have begun to see the first examples of the application of whole-genome sequencing to personalized diagnosis and therapeutics. The exponential decline in sequencing costs and the constant improvement in these technologies promise to further advance the use of a patient's full genetic profile in the clinic. However, realizing the potential benefit of such sequencing will require a concerted effort by science, medicine, law, and management. In this review, we discuss current approaches to decoding the 6 billion-letter genetic code of a whole genome in a clinical context, give current examples of translating this information into therapy-guiding knowledge, and list the challenges that will need to be surmounted before these powerful data can be fully exploited to forward the goals of personalized medicine.


Subject(s)
Drug Therapy/trends , Genome, Human/genetics , Precision Medicine/trends , Antineoplastic Agents/therapeutic use , DNA/genetics , Genetic Testing , Genetic Variation , Genomic Structural Variation , Humans , Neoplasms/drug therapy , Neoplasms/genetics , Pharmacogenetics , Polymorphism, Single Nucleotide , Preventive Medicine , Pseudogenes/genetics , Repetitive Sequences, Nucleic Acid
8.
Lancet Infect Dis ; 12(5): 388-96, 2012 May.
Article in English | MEDLINE | ID: mdl-22169409

ABSTRACT

BACKGROUND: The effects of malaria and its treatment in the first trimester of pregnancy remain an area of concern. We aimed to assess the outcome of malaria-exposed and malaria-unexposed first-trimester pregnancies of women from the Thai-Burmese border and compare outcomes after chloroquine-based, quinine-based, or artemisinin-based treatments. METHODS: We analysed all antenatal records of women in the first trimester of pregnancy attending Shoklo Malaria Research Unit antenatal clinics from May 12, 1986, to Oct 31, 2010. Women without malaria in pregnancy were compared with those who had a single episode of malaria in the first trimester. The association between malaria and miscarriage was estimated using multivariable logistic regression. FINDINGS: Of 48,426 pregnant women, 17,613 (36%) met the inclusion criteria: 16,668 (95%) had no malaria during the pregnancy and 945 (5%) had a single episode in the first trimester. The odds of miscarriage increased in women with asymptomatic malaria (adjusted odds ratio 2·70, 95% CI 2·04-3·59) and symptomatic malaria (3·99, 3·10-5·13), and were similar for Plasmodium falciparum and Plasmodium vivax. Other risk factors for miscarriage included smoking, maternal age, previous miscarriage, and non-malaria febrile illness. In women with malaria, additional risk factors for miscarriage included severe or hyperparasitaemic malaria (adjusted odds ratio 3·63, 95% CI 1·15-11·46) and parasitaemia (1·49, 1·25-1·78 for each ten-fold increase in parasitaemia). Higher gestational age at the time of infection was protective (adjusted odds ratio 0·86, 95% CI 0·81-0·91). The risk of miscarriage was similar for women treated with chloroquine (92 [26%] of 354), quinine (95 [27%) of 355), or artesunate (20 [31%] of 64; p=0·71). Adverse effects related to antimalarial treatment were not observed. INTERPRETATION: A single episode of falciparum or vivax malaria in the first trimester of pregnancy can cause miscarriage. No additional toxic effects associated with artesunate treatment occurred in early pregnancy. Prospective studies should now be done to assess the safety and efficacy of artemisinin combination treatments in early pregnancy.


Subject(s)
Antimalarials/adverse effects , Antimalarials/therapeutic use , Malaria, Falciparum/pathology , Malaria, Falciparum/prevention & control , Malaria, Vivax/pathology , Malaria, Vivax/prevention & control , Abortion, Spontaneous , Adolescent , Adult , Antimalarials/administration & dosage , Female , Humans , Malaria, Falciparum/epidemiology , Malaria, Vivax/epidemiology , Middle Aged , Myanmar/epidemiology , Pregnancy , Pregnancy Complications, Parasitic/epidemiology , Pregnancy Complications, Parasitic/pathology , Pregnancy Complications, Parasitic/prevention & control , Pregnancy Outcome , Pregnancy Trimester, First , Retrospective Studies , Thailand/epidemiology , Young Adult
9.
Science ; 320(5884): 1718, 2008 Jun 27.
Article in English | MEDLINE | ID: mdl-18583592
10.
Antimicrob Agents Chemother ; 52(3): 1052-61, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18180343

ABSTRACT

The population pharmacokinetics of piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria treated with two different dosage regimens of dihydroartemisinin-piperaquine were characterized. Piperaquine pharmacokinetics in 98 Burmese and Karen patients aged 3 to 55 years were described by a two-compartment disposition model with first-order absorption and interindividual random variability on all parameters and were similar with the three- and four-dose regimens. Children had a lower body weight-normalized oral clearance than adults, resulting in longer terminal elimination half-lives and higher total exposure to piperaquine (area under the concentration-time curve from 0 to 63 days [AUC day 0-63]). However, children had lower plasma concentrations in the therapeutically relevant posttreatment prophylactic period (AUC day 3-20) because of smaller body weight-normalized central volumes of distribution and shorter distribution half-lives. Our data lend further support to a simplified once-daily treatment regimen to improve treatment adherence and efficacy and indicate that weight-adjusted piperaquine doses in children may need to be higher than in adults.


Subject(s)
Antimalarials/pharmacokinetics , Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/drug therapy , Quinolines/pharmacokinetics , Quinolines/therapeutic use , Adolescent , Adult , Animals , Antimalarials/administration & dosage , Area Under Curve , Artemisinins/administration & dosage , Child , Child, Preschool , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Malaria, Falciparum/parasitology , Male , Middle Aged , Quinolines/administration & dosage , Thailand , Treatment Outcome
11.
Trans R Soc Trop Med Hyg ; 101(9): 858-66, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17659311

ABSTRACT

Dihydroartemisinin-piperaquine, a fixed-dose combination antimalarial, is an inexpensive, safe and highly effective treatment for uncomplicated falciparum or vivax malaria. Efficacy assessed over 28-63 days has consistently exceeded 95% in the treatment of multidrug-resistant falciparum malaria. More than 2600 patients have been treated with this combination in prospective studies, mainly in Southeast Asia. Tolerability was uniformly good, and no serious adverse effects have been identified. The dosing regimen has been simplified from four doses to once daily over 3 days. More information on efficacy in Africa, and more pharmacokinetic and efficacy data in children are needed.


Subject(s)
Antimalarials/administration & dosage , Artemisinins/administration & dosage , Malaria, Falciparum/drug therapy , Quinolines/administration & dosage , Sesquiterpenes/administration & dosage , Antimalarials/adverse effects , Artemisinins/adverse effects , Asia, Southeastern/epidemiology , Drug Combinations , Female , Humans , Male , Quinolines/adverse effects , Sesquiterpenes/adverse effects , Treatment Outcome
12.
BJOG ; 114(5): 582-7, 2007 May.
Article in English | MEDLINE | ID: mdl-17439567

ABSTRACT

OBJECTIVE: To assess the safety of benzyl benzoate lotion (BBL) and permethrin, topical treatments for scabies, during pregnancy. DESIGN: A retrospective controlled cohort study. POPULATION: Refugee and migrant women attending antenatal clinics (ANC) on the Thai-Burmese border between August 1993 and April 2006. METHODS: Women treated with either BBL (25%) or permethrin (4%) were identified from a manual search of antenatal records. Each case of scabies was matched with four scabies-free controls for gravidity, age, smoking status, malaria, period of treatment and gestational age at treatment. Conditional Poisson regression was used to estimate risk ratios for outcomes of pregnancy (proportion of abortions, congenital abnormalities, neonatal deaths, stillbirths and premature babies), mean birthweight and estimated median gestational age, for scabies and scabies-free women, independently for BBL and permethrin. RESULTS: There were no statistically significant differences in pregnancy outcomes between women who were treated with either BBL (n = 444) compared with their matched controls (n = 1,776) or permethrin (n = 196) treated women and their matched controls (n = 784). Overall, only 10.9% (n = 66) of treatments were in the first trimester. Retreatment rates were higher with BBL 16.4%, than permethrin 9.7%, P = 0.038. Scabies was more common during cooler periods. CONCLUSION: We found no evidence of adverse effects on pregnancy outcome due to topical 25% BBL or 4% permethrin.


Subject(s)
Benzoates/adverse effects , Insecticides/adverse effects , Permethrin/adverse effects , Pregnancy Complications, Parasitic/prevention & control , Scabies/prevention & control , Administration, Topical , Benzoates/administration & dosage , Case-Control Studies , Cohort Studies , Female , Humans , Insecticides/administration & dosage , Permethrin/administration & dosage , Pregnancy , Pregnancy Outcome , Refugees , Retrospective Studies
13.
Trop Med Int Health ; 12(2): 251-9, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17300633

ABSTRACT

OBJECTIVES: To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia. METHOD: Randomized open-label non-inferiority study over 64 days. RESULTS: Four hundred and sixty-four patients were included in the study. The polymerase chain reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% confidence interval, CI, 93.8-99.3) for DHA-PQP and 97.5% (95% CI, 93.8-99.3) for MAS3, P = 1. There were no serious adverse events, but significantly more episodes of vomiting (P = 0.03), dizziness (P = 0.002), palpitations (P = 0.04), and sleep disorders (P = 0.03) reported in the MAS3 treatment group, consistent with the side-effect profile of mefloquine. CONCLUSIONS: DHA-PQP was as efficacious as MAS3, but much better tolerated, making it more appropriate for use in a routine programme setting. This highly efficacious, safe and more affordable fixed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in Cambodia.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/drug therapy , Quinolines/therapeutic use , Sesquiterpenes/therapeutic use , Adolescent , Adult , Aged , Anemia/complications , Anemia/epidemiology , Antimalarials/adverse effects , Artemisinins/adverse effects , Artesunate , Cambodia/epidemiology , Child , Child, Preschool , Drug Therapy, Combination , Female , Genome, Protozoan , Humans , Infant , Malaria, Falciparum/epidemiology , Malaria, Falciparum/parasitology , Malaria, Vivax/drug therapy , Malaria, Vivax/epidemiology , Malaria, Vivax/parasitology , Male , Mefloquine/therapeutic use , Middle Aged , Quinolines/adverse effects , Recurrence , Sesquiterpenes/adverse effects , Treatment Outcome
15.
Travel Med Infect Dis ; 2(3-4): 127-42, 2004.
Article in English | MEDLINE | ID: mdl-17291974

ABSTRACT

Malaria in pregnancy contributes to significant maternal and foetal mortality and morbidity in women in the tropics. Adverse effects for non-immune travellers are potentially devastating for mother and foetus. Women travellers should always be strongly advised against visiting malarious areas if they are pregnant or intend to get pregnant. Chemoprophylactic and treatment options for pregnant women (or those planning to conceive) are extremely limited and lag behind what can currently be offered to non-pregnant travellers. This is because of spread of multi-resistant strains of P. falciparum. Personal protection from malaria vectors remains essential. Mosquito-net and skin repellents (DEET (20%)) are effective. Diagnosis of malaria in travellers is difficult and is more likely to be missed in pregnant travellers due to lower parasitaemia. Pregnant women can succumb rapidly to severe malaria. Should the returned traveller survive an episode of malaria in pregnancy and go on to deliver, the adverse effects on the infant are potentially irreversible. These risks need to be clearly communicated.

16.
Prog Cardiovasc Dis ; 44(1): 55-67, 2001.
Article in English | MEDLINE | ID: mdl-11533927

ABSTRACT

Given renewed interest in the primary prevention of cardiovascular disease, we comprehensively reviewed the utility of the electrocardiogram (ECG) for screening considering the seminal epidemiologic studies. It appears that conventional risk factors relate to long-term risk, while ECG abnormalities are better predictors of short-term risk. For individual ECG abnormalities as well as for pooled categories of ECG abnormalities, the sensitivity of the ECG for future events was too low for it to be practical as a screening tool. This almost certainly relates to the low prevalence of these abnormalities. However, all ECG abnormalities increase with age and pre-test risk. Also screening with the ECG is of minimal cost and likely to decrease further as stand-alone machines are replaced by integration into personal computers (PC). Another potential impact on performing screening ECGs would be distribution and availability of digitized ECG data via the World Wide Web. For clinical utility of ECG data, comparison with previous ECGs can be critical but is currently limited. PC based ECG systems could very easily replace many of the ECG machines in use that only have paper output. PC-ECG systems would also permit interaction with computerized medical information systems, facilitate emailing and faxing of ECGs as well as storage at a centralized web-server. Web-enabled ECG recorders similar to the new generation of home appliances could follow this quick PC solution. A serious goal for the medical industry should be to end the morass of proprietary ECG digital formats and follow a standardized format. This could lead to a network of web-servers from which every patient's ECGs would be available. Such a situation could have a dramatic effect on the advisability of performing screening ECGs.


Subject(s)
Electrocardiography , Heart Diseases/diagnosis , Mass Screening/methods , Bundle-Branch Block/diagnosis , Evidence-Based Medicine , Heart Conduction System/physiopathology , Humans , Hypertrophy, Left Ventricular/diagnosis , Hypertrophy, Left Ventricular/epidemiology , Myocardial Infarction/diagnosis , Prevalence , Retrospective Studies , Risk Factors , Sensitivity and Specificity
18.
Lancet ; 356(9241): 1592-7, 2000 Nov 04.
Article in English | MEDLINE | ID: mdl-11075788

ABSTRACT

Exercise-induced changes in the electrocardiogram have been used to identify coronary artery disease for almost a century. Over the past decade, however, clinicians have increasingly focused on more expensive diagnostic tools believing them to offer improved diagnostic accuracy. In fact, by incorporating historical data, the simple exercise test can in most cases outperform the newer tests. The use of prediction equations and non-staged exercise protocols can improve the test still further, while advances in the use of the test for prognosis, with the discovery of novel risk factors and the addition of gas analysis, may in the future shift the primary emphasis away from diagnosis. Brief, inexpensive, and done in most cases without the presence of a cardiologist, the exercise test offers the highest value for predictive accuracy of any of the non-invasive tests for coronary artery disease.


Subject(s)
Coronary Disease/diagnosis , Exercise Test , Hemodynamics , Humans , Prognosis , Risk Factors , Sensitivity and Specificity
19.
Sports Med ; 30(4): 231-48, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11048772

ABSTRACT

The exercise electrocardiogram remains the noninvasive diagnostic test of first choice in patients with coronary artery disease. While new technology offers novel diagnostic possibilities and the ability to assess patients unsuitable for exercise testing, no other investigation has to this point furnished the quality of functional information and value-for-predictive accuracy of exercise electrocardiography. In this article, we describe how this central position in the work up of the cardiac patient has been secured through the evolution of the microprocessor. Particularly important has been its ability to harness and present large volumes of raw data, to derive and manipulate multivariate equations for diagnostic prediction, and to run 'expert' systems which can pool demographic and exercise test data, calculate risk scores, and prompt the nonexpert with advice on current management. These key features explain the pivotal role of the exercise test in the diagnostic, and increasingly prognostic, armoury of the cardiovascular clinician.


Subject(s)
Coronary Disease/diagnosis , Diagnosis, Computer-Assisted , Electrocardiography , Exercise Test , Signal Processing, Computer-Assisted , Angina Pectoris/diagnosis , Coronary Disease/diagnostic imaging , Coronary Disease/physiopathology , Diagnosis, Differential , Expert Systems , Female , Heart Rate , Humans , Male , Microcomputers , Models, Cardiovascular , Prognosis , Radionuclide Imaging , Retrospective Studies , Sensitivity and Specificity , Software
20.
Med Educ ; 34(6): 455-9, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10792686

ABSTRACT

Against a background of the theoretical basis for the contextual approach to medical education, this paper examines and supports the changes that are occurring in undergraduate medical education throughout the world, before putting up for discussion the suggestion that the changes have not gone far enough. Consideration is given to a model of apprenticeship learning within undergraduate medical education, to the benefits it may offer, and to some of the challenges inherent in its implementation.


Subject(s)
Education, Medical/trends , Education, Medical, Undergraduate/trends , Humans , Learning , Mentors , Teaching/methods , Teaching/trends
SELECTION OF CITATIONS
SEARCH DETAIL
...